{"protocolSection": {"identificationModule": {"nctId": "NCT00557440", "orgStudyIdInfo": {"id": "CQMF149A2202"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER\u00ae Device in Adult Patients With Persistent Asthma", "officialTitle": "A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2009-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-11"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-11-12", "studyFirstSubmitQcDate": "2007-11-13", "studyFirstPostDateStruct": {"date": "2007-11-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-02-15", "resultsFirstSubmitQcDate": "2013-02-15", "resultsFirstPostDateStruct": {"date": "2013-03-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-02-15", "lastUpdatePostDateStruct": {"date": "2013-03-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "QMF", "Indacaterol", "Mometasone"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ind/M - FP/Salm - Pbo", "type": "EXPERIMENTAL", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period.", "interventionNames": ["Drug: fluticasone propionate/salmeterol", "Drug: indacaterol maleate / mometasone furoate", "Drug: placebo to indacaterol/mometasone", "Drug: placebo to fluticasone propionate/salmeterol"]}, {"label": "FP/Salm - Pbo - Ind/M", "type": "EXPERIMENTAL", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period.", "interventionNames": ["Drug: fluticasone propionate/salmeterol", "Drug: indacaterol maleate / mometasone furoate", "Drug: placebo to indacaterol/mometasone", "Drug: placebo to fluticasone propionate/salmeterol"]}, {"label": "Pbo - Ind/M - FP/Salm", "type": "EXPERIMENTAL", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period.", "interventionNames": ["Drug: fluticasone propionate/salmeterol", "Drug: indacaterol maleate / mometasone furoate", "Drug: placebo to indacaterol/mometasone", "Drug: placebo to fluticasone propionate/salmeterol"]}], "interventions": [{"type": "DRUG", "name": "fluticasone propionate/salmeterol", "description": "Fluticasone propionate/salmeterol 250/50 \u03bcg twice daily delivered via MDDPI.", "armGroupLabels": ["FP/Salm - Pbo - Ind/M", "Ind/M - FP/Salm - Pbo", "Pbo - Ind/M - FP/Salm"], "otherNames": ["Advair\u00ae", "Seretide\u00ae"]}, {"type": "DRUG", "name": "indacaterol maleate / mometasone furoate", "description": "Indacaterol maleate / mometasone furoate 500/400 \u03bcg once daily delivered via the TWISTHALER device.", "armGroupLabels": ["FP/Salm - Pbo - Ind/M", "Ind/M - FP/Salm - Pbo", "Pbo - Ind/M - FP/Salm"], "otherNames": ["QMF149"]}, {"type": "DRUG", "name": "placebo to indacaterol/mometasone", "description": "Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.", "armGroupLabels": ["FP/Salm - Pbo - Ind/M", "Ind/M - FP/Salm - Pbo", "Pbo - Ind/M - FP/Salm"]}, {"type": "DRUG", "name": "placebo to fluticasone propionate/salmeterol", "description": "Placebo to fluticasone propionate / salmeterol delivered via MDDPI.", "armGroupLabels": ["FP/Salm - Pbo - Ind/M", "Ind/M - FP/Salm - Pbo", "Pbo - Ind/M - FP/Salm"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from the period baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16)."}], "secondaryOutcomes": [{"measure": "Forced Expiratory Volume in 1 Second (FEV1) at Single Time Points", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "timeFrame": "5, 30 minutes, 1, 2, 3, 4 hours, 11 hours 10 minutes, 11 hours 45 minutes, 12 hours 30 minutes, 14, 16, 18, 20, 22 hours, 23 hours 10 minutes, and 23 hours 45 minutes post-dosing."}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Standardized Area Under the Curve (AUC) Between Baseline (Pre-dose) and 24 Hours Post-dose", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was measured pre-dose and up to 24 hours post-dose. The FEV1 standardized area under the curve (AUC) was analyzed for four time intervals:\n\n* Baseline (pre-dose) to 4 hours (hr) post-dosing;\n* Baseline (pre-dose) to 23 hours, 45 minutes (min) post-dosing;\n* 11 hours, 10 minutes to 12 hours, 30 minutes post-dosing;\n* 11 hours, 10 minutes to 23 hours, 45 minutes post-dosing.\n\nAUC for FEV1 was analyzed using Analysis of Covariance adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "timeFrame": "Pre-dose, 5, 30 minutes, 1, 2, 3, 4 hours, 11 hours 10 minutes, 11 hours 45 minutes, 12 hours 30 minutes, 14, 16, 18, 20, 22 hours, 23 hours 10 minutes, and 23 hours 45 minutes post-dosing."}, {"measure": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1 during the first 4 hours post-dose.\n\nTime to peak FEV1 is based on log-transformed analysis of variance adjusted for treatment, period, sequence and center, with patient nested within sequence as a random effect. Geometric Mean was obtained by taking anti-logs of the adjusted means from the model and standard error was calculated using the delta method.", "timeFrame": "Up to 4 hours post-dose"}, {"measure": "Forced Vital Capacity (FVC) at Single Time Points", "description": "Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.\n\nFVC was analyzed using ANCOVA adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "timeFrame": "5, 30 minutes, 1, 2, 3, 4 hours, 11 hours 10 minutes, 11 hours 45 minutes, 12 hours 30 minutes, 14, 16, 18, 20, 22 hours, 23 hours 10 minutes, and 23 hours 45 minutes post-dosing."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female adult patients aged 18-75 years (inclusive), who have signed an Informed Consent Form prior to initiation of any study-related procedure,\n* Patients with persistent asthma, diagnosed according to Global Initiative for Asthma (GINA) guidelines (National Institute of Health, National Heart, Lung and Blood Institute, 2006) and who additionally meet the following criteria:\n\n  * Patients receiving daily treatment with inhaled corticosteroid up to the maximum dose per day indicated in the product label, in a stable regimen for the month prior to Visit 1.\n  * Patients with an FEV1 at Visit 1 \u226550% of predicted normal.\n  * Patients who demonstrate an increase of \u2265 12% and \u2265 200 mL in FEV1 over their pre-bronchodilator.\n\nExclusion Criteria:\n\n* Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception.\n* Patients who have used tobacco products within the 6 months period prior to Visit 1, or who have a smoking history of greater than 10 pack years.\n* Patients diagnosed with Chronic Obstructive Pulmonary disease (COPD) as defined by the GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease 2006).\n* Patients with seasonal allergy whose asthma is likely to deteriorate during the study period.\n* Patients who have had an acute asthma attack/exacerbation requiring hospitalization in the 6 months prior to Visit 1.\n* Patients who have had an acute asthma attack / exacerbation requiring an emergency room visit within 6 weeks prior to Visit 1 or at any time between Visit 1 and Visit 2.\n* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1 or at any time between Visit 1 and Visit 2.\n* Patients with a history of long QT interval syndrome or whose QT interval corrected for heart rate (QTc) interval (Bazett's) measured at Visit 1 or Visit 2 is prolonged: \\> 450 ms (males) or \\> 470 ms (females).\n* Other clinically significant conditions which may interfere with the study conduct or patient safety as specified in the protocol.\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharma", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Aalst", "country": "Belgium", "geoPoint": {"lat": 50.93604, "lon": 4.0355}}, {"facility": "Novartis Investigator site", "city": "Ghent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Novartis Investigator Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigator Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Novartis Investigator Site", "city": "Landsberg", "country": "Germany", "geoPoint": {"lat": 51.52698, "lon": 12.16076}}, {"facility": "Novartis Investigator Site", "city": "Rostock", "country": "Germany", "geoPoint": {"lat": 54.0887, "lon": 12.14049}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Ind/M - FP/Salm - Pbo", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone /salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period."}, {"id": "FG001", "title": "FP/Salm - Pbo - Ind/M", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period."}, {"id": "FG002", "title": "Pbo - Ind/M - FP/Salm", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Treatment Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ind/M - FP/Salm - Pbo", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone /salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period."}, {"id": "BG001", "title": "FP/Salm - Pbo - Ind/M", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period."}, {"id": "BG002", "title": "Pbo - Ind/M - FP/Salm", "description": "In Treatment Period 1 (Days 1 \\& 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 2 (Days 8 \\& 9) participants received indacaterol/mometasone (Ind/M) 500/400 \u03bcg via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nIn Treatment Period 3 (Days 15 \\& 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 \u03bcg via MDDPI, one inhalation in the evening and one inhalation the following morning.\n\nEach treatment period was separated by a 6-day washout period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "13"}, {"groupId": "BG003", "value": "37"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.2", "spread": "15.37"}, {"groupId": "BG001", "value": "50.5", "spread": "12.00"}, {"groupId": "BG002", "value": "52.5", "spread": "10.46"}, {"groupId": "BG003", "value": "47.9", "spread": "13.51"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from the period baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "populationDescription": "The Intent-To-Treat (ITT) population included all randomized patients who had at least one period containing a Baseline FEV1 measurement and at least one post-baseline measurement of FEV1 for the same treatment period. Patients who took rescue medication within 6 hours prior to the trough measurements were excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Pre-dose for each Treatment Period (Days 1, 8 and 15) and 24-hours post-dose for each Treatment Period (Days 2, 9 and 16).", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening."}, {"id": "OG001", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to indacaterol/mometasone via the TWISTHALER device and placebo to fluticasone/salmeterol via MDDPI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.081", "spread": "0.0473"}, {"groupId": "OG001", "value": "0.049", "spread": "0.0472"}, {"groupId": "OG002", "value": "-0.083", "spread": "0.0475"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "Statistical significance (two-sided) at 5% level. p-values were not corrected for multiplicity.", "statisticalMethod": "ANCOVA", "statisticalComment": "Treatment, period, sequence and center as fixed effects, period baseline FEV1 as a covariate, and patient nested within sequence as a random effect.", "paramType": "LS Mean Difference", "paramValue": "0.165", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.066", "ciUpperLimit": "0.263", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0492"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) at Single Time Points", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "populationDescription": "Intent-to-treat population, where data were available. Patients who took rescue medication within 6 hours prior to spirometry measurements were excluded from the analysis. N indicates the number of participants with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "5, 30 minutes, 1, 2, 3, 4 hours, 11 hours 10 minutes, 11 hours 45 minutes, 12 hours 30 minutes, 14, 16, 18, 20, 22 hours, 23 hours 10 minutes, and 23 hours 45 minutes post-dosing.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening."}, {"id": "OG001", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to indacaterol/mometasone via the TWISTHALER device and placebo to fluticasone/salmeterol via MDDPI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "37"}]}], "classes": [{"title": "5 minutes [N=36, 36, 37]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.713", "spread": "0.0302"}, {"groupId": "OG001", "value": "2.632", "spread": "0.0302"}, {"groupId": "OG002", "value": "2.554", "spread": "0.0300"}]}]}, {"title": "30 minutes [N=36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.754", "spread": "0.0316"}, {"groupId": "OG001", "value": "2.719", "spread": "0.0316"}, {"groupId": "OG002", "value": "2.527", "spread": "0.0316"}]}]}, {"title": "1 hour [N=36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.760", "spread": "0.0350"}, {"groupId": "OG001", "value": "2.771", "spread": "0.0350"}, {"groupId": "OG002", "value": "2.525", "spread": "0.0350"}]}]}, {"title": "2 hours [N=36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.754", "spread": "0.0400"}, {"groupId": "OG001", "value": "2.734", "spread": "0.0399"}, {"groupId": "OG002", "value": "2.483", "spread": "0.0400"}]}]}, {"title": "3 hours [N=36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.728", "spread": "0.0411"}, {"groupId": "OG001", "value": "2.724", "spread": "0.0410"}, {"groupId": "OG002", "value": "2.425", "spread": "0.0411"}]}]}, {"title": "4 hours [N=36, 36, 35]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.705", "spread": "0.0434"}, {"groupId": "OG001", "value": "2.669", "spread": "0.0434"}, {"groupId": "OG002", "value": "2.376", "spread": "0.0437"}]}]}, {"title": "11 hours 10 minutes [N=36, 35, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.685", "spread": "0.0496"}, {"groupId": "OG001", "value": "2.570", "spread": "0.0499"}, {"groupId": "OG002", "value": "2.295", "spread": "0.0505"}]}]}, {"title": "11 hours 45 minutes [N=36, 35, 32]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.628", "spread": "0.0492"}, {"groupId": "OG001", "value": "2.518", "spread": "0.0495"}, {"groupId": "OG002", "value": "2.276", "spread": "0.0509"}]}]}, {"title": "12 hours 30 minutes [N=36, 35, 32]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.667", "spread": "0.0437"}, {"groupId": "OG001", "value": "2.659", "spread": "0.0440"}, {"groupId": "OG002", "value": "2.359", "spread": "0.0453"}]}]}, {"title": "14 hours [N=36, 35, 32]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.766", "spread": "0.0433"}, {"groupId": "OG001", "value": "2.779", "spread": "0.0436"}, {"groupId": "OG002", "value": "2.485", "spread": "0.0448"}]}]}, {"title": "16 hours [N=36, 35, 31]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.720", "spread": "0.0493"}, {"groupId": "OG001", "value": "2.681", "spread": "0.0497"}, {"groupId": "OG002", "value": "2.454", "spread": "0.0515"}]}]}, {"title": "18 hours [N=35, 36, 33]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.729", "spread": "0.0395"}, {"groupId": "OG001", "value": "2.717", "spread": "0.0389"}, {"groupId": "OG002", "value": "2.513", "spread": "0.0398"}]}]}, {"title": "20 hours [N=35, 36, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.725", "spread": "0.0475"}, {"groupId": "OG001", "value": "2.707", "spread": "0.0467"}, {"groupId": "OG002", "value": "2.479", "spread": "0.0475"}]}]}, {"title": "22 hours [N=35, 36, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.674", "spread": "0.0493"}, {"groupId": "OG001", "value": "2.695", "spread": "0.0485"}, {"groupId": "OG002", "value": "2.487", "spread": "0.0493"}]}]}, {"title": "23 hours 10 minutes [N=35, 36, 35]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.696", "spread": "0.0517"}, {"groupId": "OG001", "value": "2.676", "spread": "0.0510"}, {"groupId": "OG002", "value": "2.530", "spread": "0.0513"}]}]}, {"title": "23 hours 45 minutes [N=36, 36, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.686", "spread": "0.0459"}, {"groupId": "OG001", "value": "2.640", "spread": "0.0458"}, {"groupId": "OG002", "value": "2.523", "spread": "0.0464"}]}]}, {"title": "24 hours post-dose trough [N=36, 36, 35]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.689", "spread": "0.0473"}, {"groupId": "OG001", "value": "2.656", "spread": "0.0472"}, {"groupId": "OG002", "value": "2.524", "spread": "0.0475"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Standardized Area Under the Curve (AUC) Between Baseline (Pre-dose) and 24 Hours Post-dose", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was measured pre-dose and up to 24 hours post-dose. The FEV1 standardized area under the curve (AUC) was analyzed for four time intervals:\n\n* Baseline (pre-dose) to 4 hours (hr) post-dosing;\n* Baseline (pre-dose) to 23 hours, 45 minutes (min) post-dosing;\n* 11 hours, 10 minutes to 12 hours, 30 minutes post-dosing;\n* 11 hours, 10 minutes to 23 hours, 45 minutes post-dosing.\n\nAUC for FEV1 was analyzed using Analysis of Covariance adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "populationDescription": "Intent-to-treat population, where data were available. Patients who took rescue medication within 6 hours prior to spirometry measurements were excluded from the analysis. N indicates the number of participants with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Pre-dose, 5, 30 minutes, 1, 2, 3, 4 hours, 11 hours 10 minutes, 11 hours 45 minutes, 12 hours 30 minutes, 14, 16, 18, 20, 22 hours, 23 hours 10 minutes, and 23 hours 45 minutes post-dosing.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening."}, {"id": "OG001", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to indacaterol/mometasone via the TWISTHALER device and placebo to fluticasone/salmeterol via MDDPI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "37"}]}], "classes": [{"title": "Baseline to 4 hours [N=36, 36, 37]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.730", "spread": "0.0327"}, {"groupId": "OG001", "value": "2.713", "spread": "0.0327"}, {"groupId": "OG002", "value": "2.469", "spread": "0.0326"}]}]}, {"title": "Baseline to 23 hours, 45 minutes [N=36, 36, 37]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.718", "spread": "0.0376"}, {"groupId": "OG001", "value": "2.679", "spread": "0.0376"}, {"groupId": "OG002", "value": "2.430", "spread": "0.0374"}]}]}, {"title": "11 hr, 10 min to 12 hr, 30 min [N=36, 35, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.667", "spread": "0.0443"}, {"groupId": "OG001", "value": "2.585", "spread": "0.0445"}, {"groupId": "OG002", "value": "2.314", "spread": "0.0451"}]}]}, {"title": "11 hr, 10 min to 23 hr, 45min [N=36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.726", "spread": "0.0435"}, {"groupId": "OG001", "value": "2.696", "spread": "0.0435"}, {"groupId": "OG002", "value": "2.470", "spread": "0.0436"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1 during the first 4 hours post-dose.\n\nTime to peak FEV1 is based on log-transformed analysis of variance adjusted for treatment, period, sequence and center, with patient nested within sequence as a random effect. Geometric Mean was obtained by taking anti-logs of the adjusted means from the model and standard error was calculated using the delta method.", "populationDescription": "Intent-to-treat population, where data were available. Patients who took rescue medication within 6 hours prior to spirometry measurements were excluded from the analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "minutes", "timeFrame": "Up to 4 hours post-dose", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening."}, {"id": "OG001", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to indacaterol/mometasone via the TWISTHALER device and placebo to fluticasone/salmeterol via MDDPI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.4", "spread": "16.98"}, {"groupId": "OG001", "value": "67.7", "spread": "13.16"}, {"groupId": "OG002", "value": "22.3", "spread": "4.30"}]}]}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) at Single Time Points", "description": "Vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.\n\nFVC was analyzed using ANCOVA adjusting for treatment, period, sequence and center with period baseline as a covariate and patient nested within sequence as a random effect.", "populationDescription": "Intent-to-treat population, where data were available. Patients who took rescue medication within 6 hours prior to spirometry measurements were excluded from the analysis. N indicates the number of participants with available data at each time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "5, 30 minutes, 1, 2, 3, 4 hours, 11 hours 10 minutes, 11 hours 45 minutes, 12 hours 30 minutes, 14, 16, 18, 20, 22 hours, 23 hours 10 minutes, and 23 hours 45 minutes post-dosing.", "groups": [{"id": "OG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening."}, {"id": "OG001", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning."}, {"id": "OG002", "title": "Placebo", "description": "Participants received placebo to indacaterol/mometasone via the TWISTHALER device and placebo to fluticasone/salmeterol via MDDPI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "37"}]}], "classes": [{"title": "5 minutes [N= 36, 36, 37]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.917", "spread": "0.0333"}, {"groupId": "OG001", "value": "3.880", "spread": "0.0333"}, {"groupId": "OG002", "value": "3.830", "spread": "0.0331"}]}]}, {"title": "30 minutes [N= 36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.946", "spread": "0.0338"}, {"groupId": "OG001", "value": "3.933", "spread": "0.0338"}, {"groupId": "OG002", "value": "3.839", "spread": "0.0338"}]}]}, {"title": "1 hour [N= 36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.945", "spread": "0.0337"}, {"groupId": "OG001", "value": "3.955", "spread": "0.0337"}, {"groupId": "OG002", "value": "3.808", "spread": "0.0337"}]}]}, {"title": "2 hours [N= 36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.080", "spread": "0.1074"}, {"groupId": "OG001", "value": "3.899", "spread": "0.1073"}, {"groupId": "OG002", "value": "3.742", "spread": "0.1073"}]}]}, {"title": "3 hours [N= 36, 36, 36]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.925", "spread": "0.0390"}, {"groupId": "OG001", "value": "3.923", "spread": "0.0390"}, {"groupId": "OG002", "value": "3.708", "spread": "0.0391"}]}]}, {"title": "4 hours [N= 36, 36, 35]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.857", "spread": "0.0438"}, {"groupId": "OG001", "value": "3.861", "spread": "0.0438"}, {"groupId": "OG002", "value": "3.665", "spread": "0.0442"}]}]}, {"title": "11 hours 10 minutes [N= 36, 35, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.896", "spread": "0.0569"}, {"groupId": "OG001", "value": "3.828", "spread": "0.0573"}, {"groupId": "OG002", "value": "3.632", "spread": "0.0581"}]}]}, {"title": "11 hours 45 minutes [N= 36, 35, 32]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.837", "spread": "0.0549"}, {"groupId": "OG001", "value": "3.736", "spread": "0.0553"}, {"groupId": "OG002", "value": "3.607", "spread": "0.0570"}]}]}, {"title": "12 hours 30 minutes [N= 36, 35, 32]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.833", "spread": "0.0496"}, {"groupId": "OG001", "value": "3.841", "spread": "0.0500"}, {"groupId": "OG002", "value": "3.680", "spread": "0.0518"}]}]}, {"title": "14 hours [N= 36, 35, 32]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.918", "spread": "0.0506"}, {"groupId": "OG001", "value": "3.894", "spread": "0.0510"}, {"groupId": "OG002", "value": "3.759", "spread": "0.0528"}]}]}, {"title": "16 hours [N= 36, 35, 31]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.896", "spread": "0.0524"}, {"groupId": "OG001", "value": "3.787", "spread": "0.0528"}, {"groupId": "OG002", "value": "3.737", "spread": "0.0551"}]}]}, {"title": "18 hours [N= 35, 36, 33]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.893", "spread": "0.0462"}, {"groupId": "OG001", "value": "3.866", "spread": "0.0455"}, {"groupId": "OG002", "value": "3.784", "spread": "0.0466"}]}]}, {"title": "20 hours [N= 35, 36, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.903", "spread": "0.0499"}, {"groupId": "OG001", "value": "3.848", "spread": "0.0492"}, {"groupId": "OG002", "value": "3.764", "spread": "0.0499"}]}]}, {"title": "22 hours [N= 35, 36, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.865", "spread": "0.0453"}, {"groupId": "OG001", "value": "3.906", "spread": "0.0446"}, {"groupId": "OG002", "value": "3.764", "spread": "0.0453"}]}]}, {"title": "23 hours 10 minutes [N= 35, 36, 35]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.870", "spread": "0.0519"}, {"groupId": "OG001", "value": "3.866", "spread": "0.0512"}, {"groupId": "OG002", "value": "3.808", "spread": "0.0516"}]}]}, {"title": "23 hours 45 minutes [N=36, 36, 34]", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.866", "spread": "0.0509"}, {"groupId": "OG001", "value": "3.825", "spread": "0.0509"}, {"groupId": "OG002", "value": "3.817", "spread": "0.0516"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Indacaterol/Mometasone", "description": "Participants received a single dose of indacaterol/mometasone 500/400 \u03bcg delivered via the TWISTHALER device (2 inhalations of 250/200 \u03bcg) in the evening.", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 2, "otherNumAtRisk": 36}, {"id": "EG001", "title": "Fluticasone/Salmeterol", "description": "Participants received fluticasone/salmeterol 250/50 \u03bcg via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 1, "otherNumAtRisk": 36}, {"id": "EG002", "title": "Placebo", "description": "Participants received placebo to indacaterol/mometasone via the TWISTHALER device and placebo to fluticasone/salmeterol via MDDPI.", "seriousNumAffected": 0, "seriousNumAtRisk": 37, "otherNumAffected": 2, "otherNumAtRisk": 37}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 37}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "At 3", "relevance": "HIGH"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M245808", "name": "Maleic acid", "relevance": "LOW"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Hours per day", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}